��ndings
to be compared with those from other trials in which such
patients were not enrolled, the results demonstrated that
the 30-day stroke and death rate was signiﬁcantly lower
for patients undergoing CEA (2.6% 6 0.7% for CEA and
5.6% 6 1.0% for CAS; P ¼ .006).37 The pooled analysis of
30-day outcomes of stroke